Surveillance and monitoring of hepatocellular carcinoma.
Quantitative Liquid Chromatography/Immunoassay
New York DOH Approval Status
Serum separator tube.
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
After separation from cells: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 3 months (avoid repeated freeze/thaw cycles)
|Alpha Fetoprotein Total||0-15 ng/mL|
|Alpha Fetoprotein L3 Pct||0-9.9 percent|
The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The AFP L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. For pregnant females, the result is not interpretable as a tumor marker.
|Component Test Code*||Component Chart Name||LOINC|
|0081207||Alpha Fetoprotein Total||1834-1|
|0081209||Alpha Fetoprotein L3 Pct||42332-7|
- Alpha Fetoprotein
- Alpha Fetoprotein, Total and L3 Percent
- Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum
- Alpha-fetoprotein, Total
- Hepatocellular Carcinoma AFP
- Total AFP